文献速递免疫规划卫生政策与健康促进

2000-2020年医疗保险补充人群中吉兰-巴雷综合征患者与匹配对照的疫苗接种模式

Vaccine patterns among patients diagnosed with Guillain-Barré Syndrome and matched counterparts in a Medicare supplemental population, 2000-2020.
PubMed 文献 · Vaccine · 2023-08-10

研究匹配709名吉兰-巴雷综合征(GBS)患者与10倍无GBS对照,采用倾向评分加权比较诊断前后疫苗接种累计计数。GBS患者中7%在接种疫苗后42天内确诊;诊断后两年内GBS患者每100人接种疫苗数较对照少21剂(加权平均累计计数差-0.21剂/人,95%CI -0.24至-0.18)。尽管93%患者无免疫实践咨询委员会(ACIP)预防接种禁忌,诊断后疫苗使用仍减少,提示临床实践与现行推荐存在脱节。

要点

  • GBS患者中7%在接种疫苗后42天内确诊。
  • 诊断后两年,GBS患者每100人接种疫苗数较匹配对照少21剂(-0.21剂/人,95%CI -0.24至-0.18)。
  • 93%患者无ACIP预防接种禁忌,但诊断后疫苗使用仍减少,提示实践与推荐脱节。

核心结论

  • GBS诊断后疫苗接种减少,尽管大多数患者无ACIP预防接种禁忌,提示临床实践与现行推荐存在脱节。

研究设计与样本

  • 研究匹配709名2002至2020年确诊的GBS患者与10倍无GBS对照(1:10),按年龄和性别匹配,采用倾向评分加权平衡协变量,估计诊断前后每人疫苗接种的加权平均累计计数。

主要发现

  • GBS患者中7%在接种疫苗后42天内确诊。
  • GBS诊断前,GBS患者与匹配对照的每人疫苗接种加权平均累计计数相似。
  • 随访两年后,GBS患者每100人接种疫苗数较匹配对照少21剂(加权平均累计计数差-0.21剂/人,95%CI -0.24至-0.18)。
  • GBS患者每100人接种16剂疫苗,匹配对照每100人接种36剂。

关键数值与推荐

  • ACIP指南不将GBS视为未来接种疫苗的预防禁忌,除非GBS在含破伤风类毒素疫苗或流感疫苗接种后六周内发生。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Some vaccines have a small risk of Guillain-Barré Syndrome (GBS), a rare autoimmune disorder characterized by paralysis if untreated. The CDC's Advisory Committee on Immunization Practices (ACIP) guidelines do not consider GBS a precaution for future vaccines unless GBS developed within six weeks after a tetanus-toxoid-containing vaccine or influenza vaccine. Our goal was to describe vaccine patterns before and after GBS diagnosis. We matched each of 709 patients diagnosed with GBS from 2002 to 2020 with Medicare supplemental insurance to 10 counterparts without GBS (1:10) on age and sex. Propensity score-based weighting balanced covariates between groups, and we estimated weighted mean cumulative counts (wMCC) of vaccines/person before and after GBS diagnosis. Among patients with GBS, 7% were diagnosed within 42 days after a vaccine. Prior to GBS diagnosis, the wMCC of vaccines per person was similar between GBS cases and matched counterparts, but after two years of follow-up, GBS patients received 21 fewer vaccines/100 people than counterparts (wMCC difference -0.21 vaccines/person, 95% CI -0.24 to -0.18); GBS patients received 16 vaccines/100 people while matched counterparts received 36/100. Vaccine use was reduced following GBS diagnosis despite no ACIP precaution for most (93%) patients in this study. The observed drop in vaccines after GBS diagnosis indicates a disconnect between clinical practice and current recommendations.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Eiffert SR, Stürmer T, Thorpe CT, et al. Vaccine patterns among patients diagnosed with Guillain-Barré Syndrome and matched counterparts in a Medicare supplemental population, 2000-2020. Vaccine. 2023. PMID: 37573203. doi:10.1016/j.vaccine.2023.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。